DOCSLIB.ORG

Orexins/Hypocretins and Cancer: a Neuropeptide As Emerging Target

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orexins/Hypocretins and Cancer: a Neuropeptide As Emerging Target molecules Review Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target Couvineau Alain * , Nicole Pascal, Gratio Valérie and Voisin Thierry INSERM UMR1149/Inflammation Research Center (CRI), Team “From Inflammation to Cancer in Digestive Diseases” Labeled by “la Ligue Nationale Contre le Cancer”, University of Paris, DHU UNITY, 75018 Paris, France; [email protected] (N.P.); [email protected] (G.V.); [email protected] (V.T.) * Correspondence: [email protected] Abstract: Over 20 years ago, orexin neuropeptides (Orexin-A/hypocretin-1 and Orexin-B/hypocretins-2) produced from the same precursor in hypothalamus were identified. These two neurotransmitters and their receptors (OX1R and OX1R), present in the central and peripheral nervous system, play a major role in wakefulness but also in drug addiction, food consumption, homeostasis, hormone secretion, reproductive function, lipolysis and blood pressure regulation. With respect to these biological functions, orexins were involved in various pathologies encompassing narcolepsy, neurodegenerative diseases, chronic inflammations, metabolic syndrome and cancers. The expression of OX1R in various cancers including colon, pancreas and prostate cancers associated with its ability to induce a proapoptotic activity in tumor cells, suggested that the orexins/OX1R system could have a promising therapeutic role. The present review summarizes the relationship between cancers and orexins/OX1R system as an emerging target. Keywords: orexins; neuropeptide; GPCR; apoptosis; cancer; gastroenterology Citation: Alain, C.; Pascal, N.; Valérie, G.; Thierry, V. Orexins/ Hypocretins and Cancer: A Neuropeptide as Emerging Target. 1. Introduction Molecules 2021, 26, 4849. https:// The identification of orexin, also termed hypocretin, is still young in science history [1]. doi.org/10.3390/molecules26164849 It was in the late 1990s, when two independent groups identified and characterized these neuropeptides in mouse hypothalamus [2,3]. Orexins (for more clarity in this text, the Academic Editor: Katalin single term “orexin” will be retained) were encoded by the same gene (hcrt) constituted Prokai-Tatrai of two exons producing a unique precursor named prepro-orexin which provided two peptide isoforms, orexin-A (OxA also termed hypocretin-1) and orexin-B (OxB also termed Received: 2 July 2021 hypocretin-2) [4]. The major role of orexins in the central nervous system (CNS) is to Accepted: 6 August 2021 Published: 11 August 2021 regulate wakefulness [5]. The dysregulation of orexin production in hypothalamus as well as the loss of orexins neurons leads to narcolepsy associated with cataplexy designated as Publisher’s Note: MDPI stays neutral narcolepsy type I [5]. [In addition to sleep regulation, orexins control energy homeostasis, with regard to jurisdictional claims in reward seeking, food consumption, drug addiction and motivation [6,7]. Although the published maps and institutional affil- central action of orexins has been widely described, some studies have demonstrated that iations. orexins also play a physiological role in the peripheral nervous system (6). Orexins are able to regulate reproductive and neuroendocrine functions, gastrointestinal motility, blood pressure, metabolism and energy balance. However, few reports have been dedicated to orexins’ role in the peripheral nervous system, indicating that these peripheral actions remain relatively controversial [6]. Orexins mediate these biological actions by activating Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. two orexin receptor subtypes that have been identified as orexin receptor type 1 (OX1R) This article is an open access article and orexin receptor type 2 (OX2R). These two receptors are associated with Gq protein distributed under the terms and and belong to the G protein-coupled receptor (GPCR) family [8]. The activation of these 2+ conditions of the Creative Commons receptors by orexins leads to the production of intracellular Ca , involving the activation Attribution (CC BY) license (https:// of αq, the phospholipase C and inositol triphosphate (IP3) production (Figure1)[8]. creativecommons.org/licenses/by/ Since the 2000s, it has been shown, in pathological conditions, that OX1R (but not 4.0/). OX2R) is abnormally expressed in peripheral cancers [9]. This ectopic expression of OX1R Molecules 2021, 26, 4849. https://doi.org/10.3390/molecules26164849 https://www.mdpi.com/journal/molecules Molecules 2021, 26, 4849 2 of 10 has been observed in inflammation states, including intestinal bowel diseases (IBD), multi- ple sclerosis, pancreatitis and also in digestive cancers such as colon, pancreas and liver cancers [4,10,11] and non-digestive cancers such as prostate cancer [12]. The activation of this ectopically expressed OX1R induces anti-inflammatory and anti-tumoral effects, Molecules 2021, 26, x FOR PEER REVIEW 2 of 11 demonstrating its putative therapeutic interest in treatment of these pathologies, in par- ticular, in cancer [6,13]. A recent report focused on the connection between narcolepsy, Alzheimer’s and Parkinson’s diseases—where a dysregulation of orexin signaling was observed—andactivation of these cancer, receptors suggesting by orexins that the leads modulation to the production of orexin signalingof intracellular could Ca have2+, in- a putativevolving therapeuticthe activation role of in α cancerq, the phospholipase treatment [14]. C In and this inositol respect, triphosphate the present review (IP3) produc- reports thetion anti-tumoral (Figure 1) [8]. role of the orexins/OX1R system in various cancers. Figure 1. Structure of orexins and their receptors and main signaling pathways activated by orexins in cancer cells. DsB, disulfide bridge; IP3, inositol tri-phosphate; PLC, phospholipase; SHP2, Src ho- Figure 1. Structure of orexins and their receptors and main signaling pathways activated by orexins mologyin cancer 2 (SH2) cells. domainsDsB, disulfide of SH2-containing bridge; IP3, phosphatase inositol tri-phosphate; 2; cAMP, cyclic PLC, adenosine phospholipase; monophosphate; SHP2, Src Akt,homology protein 2 kinase (SH2) B;domains JNKs, c-jun of SH2-containing N-terminal kinases; phosphatase ERK1/2, 2; extracellular cAMP, cyclic signal-regulated adenosine monophos- kinase 1phate; and 2; Akt, ITIM, protein immunoreceptor kinase B; JNKs, tyrosine-based c-jun N-terminal motifs; kinases; Src, Src ERK1/2, kinases. extracellular signal-regulated kinase 1 and 2; ITIM, immunoreceptor tyrosine-based motifs; Src, Src kinases. 2. Orexins and Orexin Receptors OrexinsSince the (OxA 2000s, and it OxB)has been are encodedshown, in by pa thethological same mRNA conditions, which that produced OX1R (but a com- not monOX2R) precursor is abnormally [2]. OxA expressed is a peptide in peripheral of 33 amino cancers acids [9]. that This has ectopic a pyroglutamyl expression residueof OX1R inhas the been N-terminal observed position, in inflammation two disulfide states, bridges including between intestinal C6–C12 bowel and diseases C7–C14, (IBD), and mul- an amidatedtiple sclerosis, C-terminal pancreatitis end (Figure and also1)[ in15 digest]. OxBive iscancers a peptide such of as 28 colon, amino pancreas acids that and alsoliver hascancers a C-terminal [4,10,11] endand amidatednon-digestive (Figure cancers1)[ 3 such]. These as prostate two peptides cancer are[12]. highly The activation conserved of inthis all ectopically mammalians expressed [15]. It should OX1R be induces noted thatanti-inflammatory orexin-like genes and are anti-tumoral not found in effects, inver- α tebratesdemonstrating [15]. Solution its putative structures therapeutic of OxA interest and OxB in treatment reveal the of presence these pathologies, of two -helices in par- betweenticular, in residues cancer S13-G22 [6,13]. A and recent G24-T32 report for focused OxA and on residues the connection G6-S18 and between H21-T27 narcolepsy, for OxB α (FigureAlzheimer’s1). These and twoParkinson’s-helice diseases—where domains are linked a dysregulation by a small flexible of orexin domain signaling(Figure was 1ob-) . Structure–function relationship analyses of OxB revealed that the C-terminal domain N20- served—and cancer, suggesting that the modulation of orexin signaling could have a pu- M28 is crucial for the peptide activity [16]. However, the N-terminal moiety of OxB from tative therapeutic role in cancer treatment [14]. In this respect, the present review reports residue R1 to G6 is not essential for its activity [16]. As mentioned in the introduction, these the anti-tumoral role of the orexins/OX1R system in various cancers. two peptides are able to interact with two receptor subtypes, OX1R and OX2R. OX1R had a better affinity for OxA than OxB, whereas OX2R had the same affinity for two peptides [8]. 2. Orexins and Orexin Receptors Associated with the strong impact of orexins on sleep regulation, inhibition of orexin receptorsOrexins represents (OxA and an important OxB) are encoded therapeutic by optionthe same to mRNA treat insomnia which produced [17]. In this a common context, pharmaceuticalprecursor [2]. OxA industries, is a peptide but also of academic33 amino laboratories,acids that has have a pyroglutamyl developed various residue antago- in the nistsN-terminal that are position, able to regulate two disulfide wake–sleep bridges cycles between [18]. C6–C12 Many molecules and C7–C14, have and been an produced amidated C-terminal end (Figure 1) [15]. OxB is a peptide of 28 amino acids that also has a C-termi-
Load more

Recommended publications
  • Pipeline of Medications to Treat Substance Use Disorders
    Pipeline of Medications to Treat Substance Use Disorders Iván D. Montoya, M.D., M.P.H. Clinical Director and Deputy Director Division of Therapeutics and Medical Consequences NIDA • Cocaine Outline • Methamphetamine • Cannabis Past-Year Prevalence Per 1,000 1,000 People Per NSDUH, 2018 Past-Year Prevalence Per 1,000 1,000 People Per NSDUH, 2018 Number of Overdose Deaths CDC, 2018 Molecular Neurobiology of Stimulant Use Disorders Glutamate Enkephalin or Excitatory Input Dynorphin Inhibitory Neuron k Opioid Dopamine Receptors Enkephalin Receptors Inhibitory Dopamine Neuron GABA Neuron Neuron m Opioid REWARD Receptors GABA-A Receptors GABA Inhibitory Feedback GABA Presynaptic Inhibitory Opioid Neuron Receptors (m, d?) Ventral Tegmental Area Nucleus Accumbens (VTA) (NAc) Adapted from Koop, 2016 • 5HT2c Agonist - Lorcaserin (Belviq XR®) • Orexin 1 antagonists Cocaine • EMB-101 (Oxazepam + Metyrapone) • Buprenorphine + Opioid Antagonist – Clinical Studies • Ketamine • Oxytocin • L-Tetrahydropalmatine (L-THP) 5-HT2C Agonist - Lorcaserin • Clinically available • Selective agonist • Modulate mesolimbic dopamine, decreasing dopamine release • FDA-approved for weight loss • Lorcaserin (Belviq®)10 mg bid • Lorcaserin XR (Belviq XR®) 20 mg qd • Schedule IV • Arena Pharmaceuticals - Eisai Inc. Lorcaserin Pre-clinical Studies - Stimulants • Decrease cocaine self-administration and the reinstatement of responding for cocaine (Grottick et al., 2000; Burmeister et al., 2004; Burbassi and Cervo 2008; Cunningham et al., 2011; Manvich et al., 2012; RüediBettschen
    [Show full text]
  • Neuroendocrine and Sympathetic Responses to an Orexin Receptor Antagonist, SB-649868, and Alprazolam Following Insulin-Induced Hypoglycemia in Humans
    Psychopharmacology (2014) 231:3817–3828 DOI 10.1007/s00213-014-3520-7 ORIGINAL INVESTIGATION Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans Ameera X. Patel & Sam R. Miller & Pradeep J. Nathan & Ponmani Kanakaraj & Antonella Napolitano & Philip Lawrence & Annelize Koch & Edward T. Bullmore Received: 8 October 2013 /Accepted: 24 February 2014 /Published online: 26 April 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract it has previously been validated using the insulin tolerance test Rationale The orexin-hypocretin system is important for (ITT) model in humans. translating peripheral metabolic signals and central neuronal Results Of the primary endpoints, ITT induced defined in- inputs to a diverse range of behaviors, from feeding, motiva- creases in pulse rate, plasma cortisol, and adrenocorticotropic tion and arousal, to sleep and wakefulness. Orexin signaling is hormone in the placebo condition, but these responses were thus an exciting potential therapeutic target for disorders of not significantly impacted by alprazolam or SB-649868 pre- sleep, feeding, addiction, and stress. treatment. Of the secondary endpoints, ITT induced a defined Objectives/methods Here, we investigated the low dose phar- increase in plasma concentrations of adrenaline, noradrena- macology of orexin receptor antagonist, SB-649868, on neu- line, growth hormone (GH), and prolactin in the placebo roendocrine, sympathetic nervous system, and behavioral re- condition. Alprazolam pre-treatment significantly reduced sponses to insulin-induced hypoglycemic stress, in 24 healthy the GH response to ITT (p<0.003), the peak electromyogra- male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m2), phy (p<0.0001) and galvanic skin response (GSR, p=0.04)to using a randomized, double-blind, placebo-controlled, acoustic startle, the resting GSR (p=0.01), and increased within-subject crossover design.
    [Show full text]
  • The Rac Gtpase in Cancer: from Old Concepts to New Paradigms Marcelo G
    Published OnlineFirst August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-1456 Cancer Review Research The Rac GTPase in Cancer: From Old Concepts to New Paradigms Marcelo G. Kazanietz1 and Maria J. Caloca2 Abstract Rho family GTPases are critical regulators of cellular func- mislocalization of Rac signaling components. The unexpected tions that play important roles in cancer progression. Aberrant pro-oncogenic functions of Rac GTPase-activating proteins also activity of Rho small G-proteins, particularly Rac1 and their challenged the dogma that these negative Rac regulators solely regulators, is a hallmark of cancer and contributes to the act as tumor suppressors. The potential contribution of Rac tumorigenic and metastatic phenotypes of cancer cells. This hyperactivation to resistance to anticancer agents, including review examines the multiple mechanisms leading to Rac1 targeted therapies, as well as to the suppression of antitumor hyperactivation, particularly focusing on emerging paradigms immune response, highlights the critical need to develop ther- that involve gain-of-function mutations in Rac and guanine apeutic strategies to target the Rac pathway in a clinical setting. nucleotide exchange factors, defects in Rac1 degradation, and Cancer Res; 77(20); 5445–51. Ó2017 AACR. Introduction directed toward targeting Rho-regulated pathways for battling cancer. Exactly 25 years ago, two seminal papers by Alan Hall and Nearly all Rho GTPases act as molecular switches that cycle colleagues illuminated us with one of the most influential dis- between GDP-bound (inactive) and GTP-bound (active) forms. coveries in cancer signaling: the association of Ras-related small Activation is promoted by guanine nucleotide exchange factors GTPases of the Rho family with actin cytoskeleton reorganization (GEF) responsible for GDP dissociation, a process that normally (1, 2).
    [Show full text]
  • Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
    REVIEW ARTICLE published: 25 December 2013 doi: 10.3389/fphar.2013.00163 Orexin receptor antagonists as therapeutic agents for insomnia Ana C. Equihua 1, Alberto K. De La Herrán-Arita 2 and Rene Drucker-Colin 1* 1 Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México 2 Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA Edited by: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining Christopher J. Winrow, Merck, USA sleep, or non-restorative sleep with impairment of daytime functioning. Currently, Reviewed by: treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) Matthew R. Ebben, Weill Medical and pharmacological therapy. Among pharmacological interventions, the most evidence College of Cornell University, USA Gabriella Gobbi, McGill University, exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although Canada concerns persist regarding their safety and their limited efficacy. The use of these Matt Carter, University of hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) Washington, USA neuropeptides have been shown to regulate transitions between wakefulness and Michihiro Mieda, Kanazawa University, Japan sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the *Correspondence: development of a new class of pharmacological agents that antagonize the physiological Rene Drucker-Colin, Departamento effects of orexin. The development of these agents may lead to novel therapies for de Neurociencias, Instituto de insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed Fisiología Celular, Universidad arousal, and motor balance difficulties). However, antagonizing a system that regulates Nacional Autónoma de México, Circuito exterior S/N, Apdo.
    [Show full text]
  • A GTP-State Specific Cyclic Peptide Inhibitor of the Gtpase Gαs
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.25.054080; this version posted April 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A GTP-state specific cyclic peptide inhibitor of the GTPase Gαs Shizhong A. Dai1,2†, Qi Hu1,2†, Rong Gao3†, Andre Lazar1,4†, Ziyang Zhang1,2, Mark von Zastrow1,4, Hiroaki Suga3*, Kevan M. Shokat1,2* 5 1Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA 2Howard Hughes Medical Institute 3Department of Chemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan 10 4Department of Psychiatry, University of California, San Francisco, San Francisco, CA, 94158, USA *Correspondence to: [email protected], [email protected] †These authors contributed equally. 15 20 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.25.054080; this version posted April 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract: The G protein-coupled receptor (GPCR) cascade leading to production of the second messenger cAMP is replete with pharmacologically targetable receptors and enzymes with the exception of the stimulatory G protein α subunit, Gαs.
    [Show full text]
  • Bradykinin Receptor Deficiency Or Antagonism Do Not Impact the Host
    Ding et al. Intensive Care Medicine Experimental (2019) 7:14 Intensive Care Medicine https://doi.org/10.1186/s40635-019-0228-3 Experimental RESEARCH Open Access Bradykinin receptor deficiency or antagonism do not impact the host response during gram-negative pneumonia-derived sepsis Chao Ding1,2, Jack Yang2, Cornelis van’t Veer2 and Tom van der Poll2,3* * Correspondence: t.vanderpoll@ amc.uva.nl Abstract 2Center of Experimental and Molecular Medicine, Academic Background: Kinins are short peptides with a wide range of proinflammatory Medical Center, University of properties that are generated from kininogens in the so-called kallikrein-kinin system. Amsterdam, Meibergdreef 9, Room Kinins exert their biological activities through stimulation of two distinct receptor G2-130, 1105 AZ Amsterdam, the Netherlands subtypes, the kinin or bradykinin B1 and B2 receptors (B1R, B2R). Acute challenge 3Division of Infectious Diseases, models have implicated B1R and B2R in the pathogenesis of sepsis. However, their Academic Medical Center, role in the host response during sepsis originating from the lung is not known. University of Amsterdam, Amsterdam, the Netherlands Results: To determine the role of B1R and B2R in pneumonia-derived sepsis, B1R/ Full list of author information is B2R-deficient mice and wild-type mice treated with the B1R antagonist R-715 or the available at the end of the article B2R antagonist HOE-140 were studied after infection with the common gram- negative pathogen Klebsiella pneumoniae via the airways. Neither B1R/B2R deficiency nor B1R or B2R inhibition influenced bacterial growth at the primary site of infection or dissemination to distant body sites.
    [Show full text]
  • An Explanation of G-Protein Coupled Receptor Structure
    Journal of Stem Cell Research & Therapeutics Review Article Open Access Role of GPCRS towards cell: an explanation of g-protein coupled receptor structure Abstract Volume 2 Issue 3 - 2017 G- protein coupled receptors are the heptahelical, serpentine receptor and are Nidhi Sharma,1 Anil Kumar Sahdev,2 Vinit Raj2 multifunctional receptors having modulatory activity of a wide variety of biological 1Dr. K. N. Modi Institute of Pharmacy & Research centre, process including: Neurotransmission, Chemoattraction, Cardiac function, Olfaction Modinagar, India. and Vision etc. At largest level they are involved in signal transduction across cell 2Department of Pharmaceutical Sciences, Babasaheb Bhimrao membranes therefore they represent major targets in the development of novel drug Ambedkar University, India candidates in all clinical areas. Particularly membrane cholesterol has been reported to have a great role in the functioning of a number of GPCRs. Apart from this it also Correspondence: Vinit Raj, Department of Pharmaceutical have some drawbacks. Mutations that occur are associated with a broad spectrum of Sciences, Babasaheb Bhimrao Ambedkar University, VidyaVihar, diseases of diverse etiology. As a mutations result, there is a change in receptor activity Rae Bareli Road, Lucknow-226025, Email [email protected] (GPCR become inactive, overactive, or constitutively active), in the process of ligand binding and signal transduction. Changes in the GPCRs functioning can cause diseases Received: January 31, 2017 | Published: March 27, 2017 such as retinitis pigmentosa (rhodopsin mutations), nephrogenic diabetes insipidus (vasopressin receptor mutations), and obesity (melanocortin receptor mutations). Keywords: gpcrs, serpentine receptor, neurotransmission, retinitis pigmentosa, nephrogenic diabetes insipidus, bardet-biedl syndrome, hypogonadism Introduction deliver a message and appropriate cellular and physiological response1,2 (Figure 1).
    [Show full text]
  • The Hypothalamus and the Regulation of Energy Homeostasis: Lifting the Lid on a Black Box
    Proceedings of the Nutrition Society (2000), 59, 385–396 385 CAB59385Signalling39612© NutritionInternationalPNSProceedings Society in body-weight 2000 homeostasisG. of the Nutrition Williams Society et (2000)0029-6651©al.385 Nutrition Society 2000 593 The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box Gareth Williams*, Joanne A. Harrold and David J. Cutler Diabetes and Endocrinology Research Group, Department of Medicine, The University of Liverpool, Liverpool L69 3GA, UK Professor Gareth Williams, fax +44 (0)151 706 5797, email [email protected] The hypothalamus is the focus of many peripheral signals and neural pathways that control energy homeostasis and body weight. Emphasis has moved away from anatomical concepts of ‘feeding’ and ‘satiety’ centres to the specific neurotransmitters that modulate feeding behaviour and energy expenditure. We have chosen three examples to illustrate the physiological roles of hypothalamic neurotransmitters and their potential as targets for the development of new drugs to treat obesity and other nutritional disorders. Neuropeptide Y (NPY) is expressed by neurones of the hypothalamic arcuate nucleus (ARC) that project to important appetite-regulating nuclei, including the paraventricular nucleus (PVN). NPY injected into the PVN is the most potent central appetite stimulant known, and also inhibits thermogenesis; repeated administration rapidly induces obesity. The ARC NPY neurones are stimulated by starvation, probably mediated by falls in circulating leptin and insulin (which both inhibit these neurones), and contribute to the increased hunger in this and other conditions of energy deficit. They therefore act homeostatically to correct negative energy balance. ARC NPY neurones also mediate hyperphagia and obesity in the ob/ob and db/db mice and fa/fa rat, in which leptin inhibition is lost through mutations affecting leptin or its receptor.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Clinical Utility of Recently Identified Diagnostic, Prognostic, And
    Modern Pathology (2017) 30, 1338–1366 1338 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms Arantza Onaindia1, L Jeffrey Medeiros2 and Keyur P Patel2 1Instituto de Investigacion Marques de Valdecilla (IDIVAL)/Hospital Universitario Marques de Valdecilla, Santander, Spain and 2Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA Genomic profiling studies have provided new insights into the pathogenesis of mature B-cell neoplasms and have identified markers with prognostic impact. Recurrent mutations in tumor-suppressor genes (TP53, BIRC3, ATM), and common signaling pathways, such as the B-cell receptor (CD79A, CD79B, CARD11, TCF3, ID3), Toll- like receptor (MYD88), NOTCH (NOTCH1/2), nuclear factor-κB, and mitogen activated kinase signaling, have been identified in B-cell neoplasms. Chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, Waldenström macroglobulinemia, hairy cell leukemia, and marginal zone lymphomas of splenic, nodal, and extranodal types represent examples of B-cell neoplasms in which novel molecular biomarkers have been discovered in recent years. In addition, ongoing retrospective correlative and prospective outcome studies have resulted in an enhanced understanding of the clinical utility of novel biomarkers. This progress is reflected in the 2016 update of the World Health Organization classification of lymphoid neoplasms, which lists as many as 41 mature B-cell neoplasms (including provisional categories). Consequently, molecular genetic studies are increasingly being applied for the clinical workup of many of these neoplasms. In this review, we focus on the diagnostic, prognostic, and/or therapeutic utility of molecular biomarkers in mature B-cell neoplasms.
    [Show full text]
  • The Pharmacoeconomic Burden of Insomnia
    The Pharmacoeconomic Burden of Insomnia: Current Treatment Challenges and an Update on Safe and Efficacious Options © 2020. All rights reserved. No part of this report may be reproduced or distributed without the expressed written permission of PTCE. Faculty Information Julie A. Dopheide, PharmD, BCPP, FASHP Douglas S. Burgoyne, PharmD, FAMCP Professor of Clinical Pharmacy, Adjunct Associate Professor Psychiatry and the Behavioral Sciences Department of Pharmacotherapy University of Southern California School University of Utah College of Pharmacy of Pharmacy and Keck School of Medicine Salt Lake City, Utah Los Angeles, California This activity is supported by an educational grant from Eisai. Educational Objectives After completion of this activity, participants will be able to: • Characterize the pathophysiology, epidemiology, and disease burden of insomnia including the impact on quality of life in vulnerable patient groups • Identify appropriate pharmacotherapy for insomnia based on guideline recommendations, drug efficacy and safety profiles, and patient factors • Examine the economic burden of insomnia and impact of available treatment options, including effects on vulnerable patient groups Insomnia Overview Julie Dopheide, PharmD, BCPP, FASHP Emily Morris, 16 years old Emily Morris, 16 years old 2020 National Sleep Foundation Poll Shows High Levels of Daytime Sleepiness and Negative Health Impact #1 Cause of Daytime Sleepiness: Insomnia Health Impacts of Feeling Sleepy Feeling Sleepy How Many Days Per Week? 5-7 days 28% 28% 2-4 days 44% 0-1 days 0 20 40 60 1-2 days 2-4 days 5-7 days Feeling Unwell Headache Irritability Sleep in America Poll 2020. National Sleep Foundation. Published March 2020. Accessed October 8, 2020.
    [Show full text]
  • Activation of Orexin System Facilitates Anesthesia Emergence and Pain Control
    Activation of orexin system facilitates anesthesia emergence and pain control Wei Zhoua,1, Kevin Cheunga, Steven Kyua, Lynn Wangb, Zhonghui Guana, Philip A. Kuriena, Philip E. Bicklera, and Lily Y. Janb,c,1 aDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94143; bDepartment of Physiology, University of California, San Francisco, CA 94158; and cHoward Hughes Medical Institute, University of California, San Francisco, CA 94158 Contributed by Lily Y. Jan, September 10, 2018 (sent for review May 22, 2018; reviewed by Joseph F. Cotten, Beverley A. Orser, Ken Solt, and Jun-Ming Zhang) Orexin (also known as hypocretin) neurons in the hypothalamus Orexin neurons may play a role in the process of general an- play an essential role in sleep–wake control, feeding, reward, and esthesia, especially during the recovery phase and the transition energy homeostasis. The likelihood of anesthesia and sleep shar- to wakefulness. With intracerebroventricular (ICV) injection or ing common pathways notwithstanding, it is important to under- direct microinjection of orexin into certain brain regions, pre- stand the processes underlying emergence from anesthesia. In this vious studies have shown that local infusion of orexin can shorten study, we investigated the role of the orexin system in anesthe- the emergence time from i.v. or inhalational anesthesia (19–23). sia emergence, by specifically activating orexin neurons utilizing In addition, the orexin system is involved in regulating upper the designer receptors exclusively activated by designer drugs airway patency, autonomic tone, and gastroenteric motility (24). (DREADD) chemogenetic approach. With injection of adeno- Orexin-deficient animals show attenuated hypercapnia-induced associated virus into the orexin-Cre transgenic mouse brain, we ventilator response and frequent sleep apnea (25).
    [Show full text]